Fierlbeck G, Rassner G
Universitäts-Hautklinik Tübingen.
Z Hautkr. 1987 Sep 1;62(17):1280-7.
29 patients suffering from condylomata acuminata were systemically treated with human gamma-interferon obtained by means of gene technology. The daily dose, subcutaneous applied, amounted to 100 or 200 micrograms. 12 patients were completely cleared by surgical excision and additionally treated with gamma-interferon for 7 days. 3 of them developed recurrences. 17 patients were exclusively treated with gamma-interferon 100 or 200 micrograms daily; they underwent 6 courses of therapy, each lasting 7 days, with interruptions of 3-5 weeks of observation. As a result, 5 patients showed complete remission; 2 patients partially responded. The tolerance of the drug depended on the dose. We did not observe any toxic side effects. Our findings suggest that gamma-interferon subcutaneously given may be effective with genital warts.
29例尖锐湿疣患者接受了通过基因技术获得的人γ干扰素的全身治疗。皮下给药的日剂量为100或200微克。12例患者通过手术切除完全清除，并额外接受γ干扰素治疗7天。其中3例复发。17例患者仅接受每日100或200微克γ干扰素治疗；他们接受了6个疗程的治疗，每个疗程持续7天，观察期中断3 - 5周。结果，5例患者完全缓解；2例患者部分有效。药物耐受性取决于剂量。我们未观察到任何毒副作用。我们的研究结果表明，皮下注射γ干扰素可能对尖锐湿疣有效。
